The estimated Net Worth of Gunnar F. Kaufmann is at least $919 Tisíc dollars as of 12 June 2023. Dr Kaufmann owns over 28,000 units of Oncternal Therapeutics stock worth over $393,587 and over the last 5 years he sold ONCT stock worth over $0. In addition, he makes $525,886 as Chief Scientific Officer at Oncternal Therapeutics.
Dr has made over 1 trades of the Oncternal Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 28,000 units of ONCT stock worth $9,800 on 12 June 2023.
The largest trade he's ever made was buying 28,000 units of Oncternal Therapeutics stock on 12 June 2023 worth over $9,800. On average, Dr trades about 3,111 units every 0 days since 2019. As of 12 June 2023 he still owns at least 94,726 units of Oncternal Therapeutics stock.
You can see the complete history of Dr Kaufmann stock trades at the bottom of the page.
Dr. Gunnar F. Kaufmann Ph.D. is the Chief Scientific Officer at Oncternal Therapeutics.
As the Chief Scientific Officer of Oncternal Therapeutics, the total compensation of Dr D at Oncternal Therapeutics is $525,886. There are 3 executives at Oncternal Therapeutics getting paid more, with James Breitmeyer having the highest compensation of $1,115,840.
Dr D is 45, he's been the Chief Scientific Officer of Oncternal Therapeutics since . There are 13 older and 2 younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics, Inc. is Michael Carter, 82, who is the Independent Director.
Gunnar's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.
Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer a Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
Oncternal Therapeutics executives and other stock owners filed with the SEC include: